Full Product Name
MOGS siRNA (Human)
Product Synonym Names
GCS1; Mannosyl-oligosaccharide glucosidase; Processing A-glucosidase I
Product Gene Name
MOGS sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q13724
Specificity
MOGS siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MOGS gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MOGS sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MOGS sirna
siRNA to inhibit MOGS expression using RNA interference
Applications Tested/Suitable for MOGS sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MOGS. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001139630.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001146158.1
[Other Products]
UniProt Primary Accession #
Q13724
[Other Products]
UniProt Secondary Accession #
Q17RN9; Q8TCT5; A8K938; F5H6D0[Other Products]
UniProt Related Accession #
Q13724[Other Products]
Molecular Weight
80,703 Da
NCBI Official Full Name
mannosyl-oligosaccharide glucosidase isoform 2
NCBI Official Synonym Full Names
mannosyl-oligosaccharide glucosidase
NCBI Official Symbol
MOGS??[Similar Products]
NCBI Official Synonym Symbols
DER7; GCS1; CDG2B; CWH41
??[Similar Products]
NCBI Protein Information
mannosyl-oligosaccharide glucosidase
UniProt Protein Name
Mannosyl-oligosaccharide glucosidase
UniProt Synonym Protein Names
Processing A-glucosidase I
Protein Family
Mannosyl-oligosaccharide glucosidase
UniProt Gene Name
MOGS??[Similar Products]
UniProt Synonym Gene Names
GCS1??[Similar Products]
UniProt Entry Name
MOGS_HUMAN
NCBI Summary for MOGS
This gene encodes the first enzyme in the N-linked oligosaccharide processing pathway. The enzyme cleaves the distal alpha-1,2-linked glucose residue from the Glc(3)-Man(9)-GlcNAc(2) oligosaccharide precursor. This protein is located in the lumen of the endoplasmic reticulum. Defects in this gene are a cause of type IIb congenital disorder of glycosylation (CDGIIb). Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]
UniProt Comments for MOGS
GCS1: Cleaves the distal alpha 1,2-linked glucose residue from the Glc(3)Man(9)GlcNAc(2) oligosaccharide precursor in a highly specific manner. Defects in MOGS are the cause of type IIb congenital disorder of glycosylation (CDGIIb); also known as glucosidase I deficiency. CDGIIb is characterized by marked generalized hypotonia and hypomotility of the neonate, dysmorphic features, including a prominent occiput, short palpebral fissures, retrognathia, high arched palate, generalized edema, and hypoplastic genitalia. Symptoms of the infant included hepatomegaly, hypoventilation, feeding problems and seizures. The clinical course was progressive and the infant did not survive more than a few months. Belongs to the glycosyl hydrolase 63 family.
Protein type: Glycan Metabolism - N-glycan biosynthesis; Membrane protein, integral; Hydrolase; Endoplasmic reticulum; EC 3.2.1.106
Chromosomal Location of Human Ortholog: 2p13.1
Cellular Component: endoplasmic reticulum membrane; membrane; endoplasmic reticulum; integral to membrane
Molecular Function: mannosyl-oligosaccharide glucosidase activity; glucosidase activity
Biological Process: cellular protein metabolic process; protein folding; protein amino acid N-linked glycosylation; protein amino acid N-linked glycosylation via asparagine; post-translational protein modification; oligosaccharide metabolic process
Disease: Congenital Disorder Of Glycosylation, Type Iib
Research Articles on MOGS
1. A shortened immunoglobulin half-life was determined to be the mechanism underlying the hypogammaglobulinemia in congenital disorder of glycosylation type IIb (CDG-IIb).
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
